Cost-effectiveness of bladder cancer screening

Yair Lotan; Robert S. Svatek

doi:10.1586/14737167.7.6.627

Cost-effectiveness of bladder cancer screening

Yair Lotan, Robert S. Svatek

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.

Original language	English (US)
Pages (from-to)	627-632
Number of pages	6
Journal	Expert Review of Pharmacoeconomics and Outcomes Research
Volume	7
Issue number	6
DOIs	https://doi.org/10.1586/14737167.7.6.627
State	Published - Dec 2007

Keywords

Bladder cancer
Cost-effectiveness
Screening

ASJC Scopus subject areas

Health Policy
Pharmacology (medical)

Access to Document

10.1586/14737167.7.6.627

Cite this

@article{0264f0d70963409c9cedcd8e41e61b30,

title = "Cost-effectiveness of bladder cancer screening",

abstract = "Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.",

keywords = "Bladder cancer, Cost-effectiveness, Screening",

author = "Yair Lotan and Svatek, {Robert S.}",

year = "2007",

month = dec,

doi = "10.1586/14737167.7.6.627",

language = "English (US)",

volume = "7",

pages = "627--632",

journal = "Expert Review of Pharmacoeconomics and Outcomes Research",

issn = "1473-7167",

publisher = "Expert Reviews Ltd.",

number = "6",

}

TY - JOUR

T1 - Cost-effectiveness of bladder cancer screening

AU - Lotan, Yair

AU - Svatek, Robert S.

PY - 2007/12

Y1 - 2007/12

N2 - Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.

AB - Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.

KW - Bladder cancer

KW - Cost-effectiveness

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=37549068534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549068534&partnerID=8YFLogxK

U2 - 10.1586/14737167.7.6.627

DO - 10.1586/14737167.7.6.627

M3 - Review article

C2 - 20528324

AN - SCOPUS:37549068534

SN - 1473-7167

VL - 7

SP - 627

EP - 632

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

IS - 6

ER -

Cost-effectiveness of bladder cancer screening

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this